1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Mammalian Models of Parkinson's Disease. Potential Uses and Misuses of Acute, Sub-acute, and Chronic Models

Parkinson's Disease

Volumn , Issue , 2008, Pages 87-103

  Schneider, J S ^a   Anderson, D W ^a   Decamp, E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954295106     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374028-1.00008-7     Document Type: Chapter

References (99)

1. Anderson, D. W., Schneider, J. S. (2006). Microglial activation and perpetuation of neurodegeneration in MPTP-treated mice are dependent upon toxin administration protocol, Society for Neuroscience, Vol. Program No. 75.4. Neuroscience Meeting Planner, Atlanta, GA.
2. Anderson D.W., Neavin T., Smith J.A., Schneider J.S. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res 2001, 905:44-53.
3. Anderson D.W., Bradbury K.A., Schneider J.S. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur J Neurosci 2006, 24:3174-3182.
4. Asselin M.-C., Soghomonian J.J., Cote P.Y., Parent A. Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys. Neuroreport 1994, 5:2137-2140.
5. Augood S.J., Emson P.C., Mitchell I.J., Boyce S., Clarke C.E., Crossman A. Cellular localization of enkephalin gene expression in MPTP-treated cynomologus monkeys. Mol Brain Res 1989, 6:85-92.
6. Barcia C., Sanchez Bahillo A., Fernandez-Villalba E., Bautista V., Poza Y.P.M., Fernandez-Barreiro A., Hirsch E.C., Herrero M.T. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 2004, 46:402-409.
7. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?. Ann Neurol 1992, 31:119-130.
8. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproducesfeatures of Parkinson's disease. Nat Neurosci 2000, 3:1301-1306.
9. Bezard E., Imbert C., Gross C.E. Experimental models of Parkinson's disease: From the static to the dynamic. Rev Neurosci 1998, 9:71-90.
10. Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003, 9:762-767.
11. Bezard E., Hill M.P., Crossman A.R., Brotchie J.M., Michel A., Grimee R., Klitgaard H. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol 2004, 485:159-164.
12. Bibbiani F., Oh J.D., Chase T.N. Serotonin 5HT1A agonist improves motoc complications in rodent and primate parkinsonian models. Neurology 2001, 57:1829-1834.
13. Blanchet P.J., Calon F., Morissette M., Hadj Tahar A., Belanger N., Samadi P., Grondin R., Gregoire L., Meltzer L., Di Paolo T., Bedard P.J. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat Disord 2004, 10:297-304.
14. Brecknell J.E., Dunnett S.B., Fawcett J.W. A quantitative study of cell death in the substantia nigra following a mechanical lesion of the medial forebrain bundle. Neuroscience 1995, 64:219-227.
15. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model for parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983, 80:4546-4550.
16. Caraceni T., Scigliano G., Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: Role of early treatment and disease progression. Neurology 1991, 41:380-384.
17. Carlsson A. A pharmacological depletion of catecholamine stores. Modification of Sympathetic Function 1966, Vol. 18:541-549. The Williams and Wilkins Company, New York. F.F. Shideman (Ed.).
18. Chan P., DeLanney L.E., Irwin I., Langston J.W., Di Monte D. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J Neurochem 1991, 57:348-351.
19. Chassain C., Eschalier A., Durif F. Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys. Exp Neurol 2003, 182:490-496.
20. Chiba K., Trevor A., Castagnoli N. Metabolism of the neurotoxic tertiary amine MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984, 120:574.
21. Crossman A.R., Clarke C.E., Boyce S., Robertson R.G., Sambrook M.A. MPTP-induced parkinsonism in the monkey: Neurochemical pathology, complications of treatment and pathophysiological mechanisms. Can J Neurol Sci 1987, 14:428-435.
22. Decamp E., Wade T., Schneider J.S. Differential regulation of striatal dopamine D1 and D2 receptors in acute and chronic parkinsonian monkeys. Brain Res 1999, 847:134-138.
23. Decamp E., Schneider J.S. Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. Eur J Neurosci. 2004, 20:1371-1378.
24. Dehmer T., Lindenau J., Haid S., Dichgans J., Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 2000, 74:2213-2216.
25. Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: An evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002, 175:303-317.
26. Donaldson I., Dolphin A., Jenner P., Marsden C.D., Pycock C. The roles of noradrenaline and dopamine in contraversive circling behaviour seen after unilateral electrolytic lesions of the locus coeruleus. Eur J Pharmacol 1976, 39:179-191.
27. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., Bymaster F.P., Paul S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001, 98:14669-14674.
28. Furuya T., Hayakawa H., Yamada M., Yoshimi K., Hisahara S., Miura M., Mizuno Y., Mochizuki H. Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci 2004, 24:1865-1872.
29. Galpern W.R. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006, 66:664-671. for The NINDS NET-PD Investigators.
30. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J., Sibley D.R. D-1 and D-2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990, 250:1429-1432.
31. Goetz C.G., Damier P., Hicking C., Laska E., Muller T., Olanow C.W., Rascol O., Russ H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo controlled trial Mov. Disord 2007, 22:179-186.
32. Goto K., Mochizuki H., Imai H., Akiyama H., Mizuno Y. An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced hemiparkinsonian monkeys. Brain Res 1996, 724:125-128.
33. Grondin R., Hadj Tahar A., Doan V.D., Ladure P., Bedard P.J. Noradrenoceptor antagonism with idazoxan improves l-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 2000, 361:181-186.
34. Hadj Tahar A., Belanger N., Bangassoro E., Gregoire L., Bedard P.J. Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys. Eur J Pharmacol 2000, 399:183-186.
35. Hartley A., Stone J.M., Heron C., Cooper J.M., Schapira A.H. Complex I Inhibitors induce dose-dependant apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 1994, 63:1987-1990.
36. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984, 224:1451-1453.
37. Hekkila R., Seiber B.-A., Manzino L., Sonsalla P.K. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol Chem Neuropathol 1989, 10:171.
38. Herrero M.T., Augood S.J., Hirsch E.C., Javoy-Agid F., Luquin R., Agid Y., Obeso J.A., Emson P.C. Effects of l-dopa on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 1995, 68:1189-1198.
39. Hirsch E.C., Breidert T., Rousselet E., Hunot S., Hartmann A., Michel P.P. The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003, 991:214-228.
40. Hurley S.D., O'Banion M.K., Song D.D., Arana F.S., Olschowka J.A., Haber S.N. Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys. Exptl Neurol. 2003, 184:659-668.
41. Iravani M.M., Costa S., Jackson M.J., Tel B.C., Cannizzaro C., Pearce R.K., Jenner P. GDNF reverses priming for dyskinesia in MPTP-treated, l-DOPA-primed common marmosets. Eur J Neurosci 2001, 13:597-608.
42. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4:257-269.
43. Jenner P. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism Relat Disord 2003, 9:131-137.
44. Jenner P. The MPTP-treated primate as a model of motor complications in PD: Primate model of motor complications. Neurology 2003, 61:S4-ss11.
45. Kostic V., Przedborski S., Flaster E., Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991, 41:202-205.
46. Kulak J.M., Schneider J.S. Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys. Brain Res 2004, 999:193-202.
47. Kulak J.M., Fan, Hand Schneider J.S. beta;2, β4 and B4 nicotinic acetylcholine receptor expression changes with progressive parkinsonism in non-human primates. Neurobiol Dis 2007, 27:312-319.
48. Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., Czlonkowski A., Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999, 156:50-61.
49. Langston J.W., Ballard P.A., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of merperidine-analog synthesis. Science 1983, 219:979-980.
50. Langston J.W., Forno L.S., Rebert C.S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 1984, 292:390-394.
51. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAiliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999, 5:1403-1409.
52. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984, 311:464-467.
53. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., Cory-Slechta D.A., Di Monte D.A. Environmental risk factors and Parkinson's disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002, 10:119-127.
54. McGeer P.L., Schwab C., Parent A., Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 2003, 54:599-604.
55. Meissner W., Prunier C., Guilloteau D., Chalon S., Gross C., Bezard E. Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. Mol Neurobiol 2003, 28:209-218.
56. Melamed E., Rosenthal J., Globus M., Cohen O., Frucht Y., Uzzan A. Mesolimbic dopaminergic neurons are not spred by MPTP neurotoxicity in mice. Eur J Pharmacol 1985, 114:97-100.
57. Merck KGaA: Sarizotan phase III studies did not meet primary efficacy endpoint (2007). http://www.me.merck.de/n/A720D2336B86597DC1257196001CCA99/FILE/Sarizo-e. pdf.
58. Miyawaki E., Lyons K., Pahwa R., Troster A.I., Hubble J., Smith D., Busenbark K., McGuire D., Michalek D., Koller W.C. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 1997, 20:523-530.
59. Morissette M., Grondin R., Goulet M., Bedard P.J., Di Paolo T. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J Neurochem 1999, 72:682-692.
60. Mouradian M.M., Heuser I.J., Baronti F., Chase T.N. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990, 27:18-23.
61. Nisbet A.P., Foster O.J.F., Kingsbury A., Eve D.J., Daniel S.E., Marsden C.D., Lees A.J. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 1995, 66:361-376.
62. Normand E., Popovici T., Onteniente B., Fellman D., Pieter-Tonneau D., Auffrey C., Bloch B. Dopaminergic neurons of the substantia nigra modulate preproenkephalin A gene expression in rat striatal neurons. Brain Res 1988, 439:39-46.
63. Parent A., Hazrati L.-N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Rev 1995, 20:91-127.
64. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287:1653-1661. Parkinson Study Group.
65. Pope-Coleman A., Schneider J.S. Effects of chronic GM1 ganglioside treatment on cognitive and motor deficits in a slowly progressing model of parkinsonism in non-human primates. Restor Neurol Neurosci 1998, 12:255-266.
66. Pope-Coleman A., Tinker J.P., Schneider J.S. Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys. Synapse 2000, 36:120-128.
67. Przedborski S., Vila M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: A tool to explore the pathogenesis of Parkinson's disease. Ann NY Acad Sci 2003, 991:189-198.
68. Ramsay R.R., Singer T.P. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem 1986, 261:7585-7587.
69. Ricaurte G.A., Langston J.W., Delanney L.E., Irwin I., Peroutka S.J., Forno L.S. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A neurochemical and morphological reassessment. Brain Res 1986, 376:117-124.
70. Roundtable S.T.A.I. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999, 30:2752-2758.
71. Ryan M.E., Ashley R.A. How do tetracyclines work?. Adv Dent Res 1998, 12:149-151.
72. Schneider J.S. Levodopa-induced dyskinesias in parkinsonian monkeys: Relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989, 34:193-196.
73. Schneider J.S. Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Brain Res 1990, 534:25-36.
74. Schneider J.S., Denaro F.J. Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain. J Neuropathol Exp Neurol 1988, 47:452-458.
75. Schneider J.S., Kovelowski C.J. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res 1990, 519:122-128.
76. Schneider J.S., Pope-Coleman A. Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. Neurodegeneration 1995, 4:245-255.
77. Schneider J.S., Roeltgen D.P. Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys. Brain Res 1993, 615:351-354.
78. Schneider J.S., Yuwiler A., Markham C.H. Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Behavior, histology, and biochemistry. Exp Neurol 1986, 91:293-307.
79. Schneider J.S., Yuwiler A., Markham C.H. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Brain Res 1987, 411:144-150.
80. Schneider J.S., Unguez G., Yuwiler A., Berg S.C., Markham C.H. Deficits in operant behaviour in monkeys with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Brain 1988, 111:1265-1285.
81. Schneider J.S., Rothblat D.S., DiStefano L. Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism. Brain Res 1994, 643:86-91.
82. Schneider J.S., Decamp E., Wade T. Striatal preproenkephalin gene expression is upregulatedin acute but not chronic parkinsonian monkeys: Implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomatology. J Neurosci 1999, 19:6643-6649.
83. Schneider J.S., Gonczi H., Decamp E. Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms. Brain Res 2003, 990:38-44.
84. Schneider J.S., Kulak J.M., Anderson D.W. Microglial Activation and Perpetuation of Neurodegeneration in MPTP-Treated Primates Is Dependent Upon Toxin Administration Protocol 2006, Society for Neuroscience, Atlanta, GA, pp. 75.3/GG17.
85. Seiden L.S., Ricaurte G.A. Neurotoxicity of methamphetamine and related drugs. Psychophar-macology: The Third Generation of Progress 1987, 359-366. Raven, New York. H.Y. Meltzer (Ed.).
86. Seniuk N.A., Tatton W.G., Greenwood C.E. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res 1990, 527:7-20.
87. Sonsalla P.K., Heikkila R.E. The influence of dose and dosing interval in MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol 1986, 129:339-345.
88. Sonsalla P.K., Heikkila R.E. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. Prog Neuropsychopharmacol Biol Psychiatry. 1988, 12:345-354.
89. Sweet R.D., McDowell F.H. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. Ann Intern Med 1975, 83:456-463.
90. Switzer R.C. Argyrophilic degeneration of substantia nigra neurons in C57 mice due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Society for Neuroscience, Abstr 1985, 11:992.
91. Tatton N.A., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997, 77:1037-1048.
92. Thomas M., Le W.D. Minocycline: Neuroprotective mechanisms in Parkinson's disease. Curr Pharm Des 2004, 10:679-686.
93. Tye S.J., Rupniak N.M., Naruse T., Miyaji M., Iversen S.D. NB-355: A novel prodrug for l-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys. Clin Neuropharmacol 1989, 12:393-403.
94. Wade T.V., Schneider J.S. Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs. J Neurosci 2001, 21:4901-4907.
95. Wade T.V., Schneider J.S. Striatal preprotachykinin gene expression reflects parkinsonian signs. Neuroreport 2004, 15:2481-2484.
96. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.-K., Ischiropoulos H., Przedborski S. Blockase of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002, 22:1763-1771.
97. Yang L., Sugama S., Chirichigno J.W., Gregorio J., Lorenzl S., Shin D.H., Browne S.E., Shimizu Y., Joh T.H., Beal M.F., Albers D.S. Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosci Res 2003, 74:278-285.
98. Young W.S., Bonner T.I., Brann M.R. Mesencephalic dopaminergic neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc Natl Acad Sci USA 1986, 83:9827-9831.
99. Zou L.-L., Xu J., Jankovic J., He Y., Appel S.H., Le W.-D. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra indued by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57Bl/6 mice. Neurosci Lett 2000, 281:167-170.